Hypophosphatemia in patients with chronic HBV
DOI:
https://doi.org/10.7175/rhc.v5i1S.928Keywords:
Hypophosphatemia, Chronic HBV, Nucleotide analogsAbstract
Phosphorus is an essential element for correct functioning of the organism. Alteration of serum phosphorus may be due to reduced dietary intake, altered by intra-extracellular, by excretion or reabsorption from the intestine, bone and kidney. In patients with chronic hepatitis B, hypophosphatemia may be secondary to several causes among which the most frequent are related to the use of drugs and the deficiency of vitamin D. Tenofovir is a first choice drug for the treatment of chronic hepatitis B and it can be used in patients with mild renal impairment. In fact renal failure induced by TDF is not frequent, dose-dependent and usually reversible. However, it’s recommended to avoid use other nephrotoxic drugs during treatment with TDF; monitor kidney function and phosphorus metabolism before and during therapy; adjust the doses of the drugs to the degree of renal failure; verify the presence of proximal tubulopathy through the calculation of the EFPi and the TMPi/GFR and consider the suspension of the TDF in the case of severe hypophosphoremia (< 1 mg / dl) or creatinine clearance < 50 ml/min). The aim of this review is to facilitate the recognition of druginduced hypophosphatemia and differentiate it from that due to other causes, in order to avoid unnecessary discontinuation of antiviral therapy.
References
Bagnis CI, Karie S, Deray G, et al. Hypophosphataemia: an easy strategy for diagnosis and treatment in HIV patients. Antivir Therapy 2009; 14: 481-8
Stokes C, Volmer D, Grünhage F. Vitamin D in chronic liver disease. Liver Int 2013: 33: 338-52; http://dx.doi.org/10.1111/liv.12106
Hruska KA, Mathew S, Lund R, et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008; 74: 148-57; http://dx.doi.org/10.1038/ki.2008.130
Liamis G, Milionis HJ, Elisaf M. Medication-induced hypophosphatemia: a review. QJM 2010; 103: 449-59; http://dx.doi.org/10.1093/qjmed/hcq039
Forster IC, Hernando N, Biber J, et al. Proximal tubular handling of phosphate: A molecular perspective. Kidney Int 2006; 70: 1548-59; http://dx.doi.org/10.1038/sj.ki.5001813
Donhowe JM, Freier EF, Wong ET, et al. Factitious hypophosphatemia related to mannitol therapy. Cli Chem 1981; 27: 1765-69
Liu PY, Jeng CY. Severe hypophosphatemia in a patient with diabetic ketoacidosis and acute respiratory failure. J Chin Med Assoc 2004; 67: 355-9
Paleologos M, Stone E, Braude S. Persistent, progressive hypophosphatemia after voluntary hyperventilation. Clin Sci 2000; 98: 619-25; http://dx.doi.org/10.1042/CS19990172
Marinella MA. Refeeding syndrome and hypophosphatemia. J Intensive Care Med 2005; 20: 155-9; http://dx.doi.org/10.1177/0885066605275326
Nowack R, Wachtler P. Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet--proposal for an improved monitoring. Clin Lab 2006; 52: 583-7
Amanzadeh J, Reilly RF Jr. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol 2006; 2: 136-48; http://dx.doi.org/10.1038/ncpneph0124
Lotz M, Zisman E, Bartter FC. Evidence for a phosphorus depletion syndrome in man. N Engl J Med 1968; 278: 409-15; http://dx.doi.org/10.1056/NEJM196802222780802
Chines A, Pacifici R. Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature. Calcif Tissue Int 1990; 47: 291-5; http://dx.doi.org/10.1007/BF02555911
Buell JF, Berger AC, Plotkin JS, et al. The clinical implications of hypophosphatemia following major hepatic resection or cryosurgery. Arch Surg 1998; 133: 757-61; http://dx.doi.org/10.1001/archsurg.133.7.757
Adami S, Romagnoli E, Carnevale V. Guidelines on prevention and treatment of vitamin D deficiency. Reumatismo 2011; 63: 129-47; http://dx.doi.org/10.4081/reumatismo.2011.129
Jacques J, Essig M, Carrier P. Is HBV-related renal tubulopathy before any antiviral treatment a reality? J Hepatology 2013; 58S: 229-30
Liamis G, Milionis HJ, Elisaf M. A review of drug-induced hypocalcemia. J Bone Miner Metab 2009; 27: 635-42; http://dx.doi.org/10.1007/s00774-009-0119-x
Tolman KG, Jubiz W, Sannella JJ, et al. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children. Pediatrics 1975; 56: 45-50
Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-81; http://dx.doi.org/10.1056/NEJMra070553
Pfister MF,Forgo J, Ziegler U, et al. cAMP-dependent and -independent down regulation of type II Na-Pi cotransporters by PTH. Am J Physiol 1999; 276: F720-5
Assadi F. Hypophosphatemia an evidence-based Problem-Solving Approach to Clinical Cases. Iranian Journal of Kidney Diseases 2010; 4: 195-201
Haque SK, Ariceta G, Batlle D. Proximal renal tubular acidosis: a not so rare disorder of multiple. Nephrol Dial Transplant 2012; 27: 4273-87; http://dx.doi.org/10.1093/ndt/gfs493
Izzedine H, Launay-Vacher V, Isnard-Bagnis C. Drug-Induced Fanconi’s Syndrome. Am J Kidney Dis 2003; 41: 292-309; http://dx.doi.org/10.1053/ajkd.2003.50037
Mir O, Coriat R, Boudou-Rouquette P, et al. Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications. Ann Oncol 2012; 23: 280-1; http://dx.doi.org/10.1093/annonc/mdr525
Portale AA, Halloran BP, Morris RC Jr. Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D. J Clin Invest 1987; 80: 1147-54; http://dx.doi.org/10.1172/JCI113172
Payne RB. Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation. Ann Clin Biochem 1998; 35: 201-6; http://dx.doi.org/10.1177/000456329803500203
Walton RJ, Bjivoet OLM. Nomogram for derivation of renal threshold of phosphate concentration. Lancet 1975; 2: 309-10
Pipili C, Cholongitas E, Papatheodoridis G. Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther 2014; 39: 35-46; http://dx.doi.org/10.1111/apt.12538
Frascà GM, Balestra E, Tavio M, et al. Il danno renale da farmaci antivirali. G Ital Nefrol 2012; 29: 109-14
Fontana RJ. Side Effects of Long-Term Oral Antiviral Therapy for Hepatitis B. Hepatology 2009; 49: S185-95; http://dx.doi.org/10.1002/hep.22885
Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008; 22: 99-103; http://dx.doi.org/10.1089/apc.2007.0052
Kearney BP, Mathias A, Mittan A, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2006; 43: 278-8; http://dx.doi.org/10.1097/01.qai.0000243103.03265.2b
Fisher EJ, Chaloner K, Cohn DL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 2001; 15: 1695-700; http://dx.doi.org/10.1097/00002030-200109070-00013
Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA 1999; 282: 2305-12; http://dx.doi.org/10.1001/jama.282.24.2305
Izzedine H, Hulot JS, Launay-Vacher V. Renal safety of adefovir dipivoxil in patients with chronich epatitis B: two double-blind, randomized, placebo-controlled studies. Kidney International 2004; 66: 1153-8; http://dx.doi.org/10.1111/j.1523-1755.2004.00866.x
European Association for the Study of The Liver. EASL Clinical Practice Guidelines: Management of chronich epatitis B virus infection. J Hepatology 2012; 57: 167-85; http://dx.doi.org/10.1016/j.jhep.2012.02.010
Viread: EPAR – Summary for the public. Disponibile su http://www.ema.europa.eu/
Hepsera: EPAR - Summary for the public. Disponibile su http://www.ema.europa.eu/
Marcellin P, Heathcote EJ, Buti M. Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis. N Engl J Med 2008; 359: 2442-55; http://dx.doi.org/10.1056/NEJMoa0802878
Marcellin P, Gane E, Tsai N, et al. Seven years of treatment with tenofovir disoproxil fumarate for chronic Hepatitis B Virus infection is safe and well tolerated and associated with sustained virological, biochemical, and serological responses with no detectable resistance. Hepatology 2013; 58 (S1): 649A; http://dx.doi.org/10.1002/hep.26856
Hezode C, Causse X, Larrey D, et Al. Virological response and tolerance of Tenofovir DF (TDF) in the elderly is similar to younger patients in real life practice. J Hepatol 2013; Supp 1: 58
Fung S, Kwan P, Horban A, et al. Tenofovir DF (TDF) is safe and well tolerated in chronich epatitis B (CHB) patients with pre-existing mild renal impairment. J Hepatol 2013; 58: S301-2; http:// dx.doi.org/10.1016/S0168-8278(13)60746-1
Gish R G, Clark MD, Kane SD, et al. Similar risk of renal events among patients treated with tenofoviror entecavir for chronichepatitis B. Clin Gastroenterol Hepatol 2012; 10: 941-6; http:// dx.doi.org/10.1016/j.cgh.2012.04.008
RCP Viread® – Informazioni e raccomandazioni sulla sicurezza renale. Disponibile su www. agenziafarmaco.gov.it/allegati/rcp_viread300408.pdf
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
